

## ASX Announcement

### VAXINIA MAST Trial clears Cohort 3 of Intratumoral Monotherapy Dose Escalation

**Sydney, Australia, 14 August 2023:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that its Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has cleared the cohort 3 intratumoral (IT) arm of the monotherapy dose escalation study.

This allows Imugene to commence recruitment for IT cohort 4 of the monotherapy dose escalation, whereby VAXINIA will be administered in three-to-six patients.

#### Dose Administration (Parallel Groups)

n=52-100



IT Administration  
Metastatic and Advanced  
Solid Tumors




IV Administration  
Metastatic and Advanced  
Solid Tumors

Site Location: USA, AUS

#### VAXINIA Monotherapy Dose Escalation



#### VAXINIA + Pembrolizumab Combination Dose Escalation\*



Imugene MD & CEO Leslie Chong said: “We continue to rapidly advance our monotherapy dose while the combination study continues its positive progress. We remain incredibly eager to bring the results of this trial to our shareholders, patients and the wider public.”

The multicenter Phase 1 MAST trial commenced by delivering a low dose of VAXINIA to patients with metastatic or advanced solid tumours who have had at least two prior lines



of standard of care treatment. The City of Hope-developed oncolytic virus has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models<sup>1</sup>. Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia.

The clinical trial is titled “A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33- hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST).” The trial commenced in May 2022 and is anticipated to run for approximately 24 months while being funded from existing budgets and resources.

Full study details can also be found on [clinicaltrials.gov](https://clinicaltrials.gov) under study ID: NCT05346484.

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
[info@imugene.com](mailto:info@imugene.com)

**Investor Enquiries**  
[shareholderenquiries@imugene.com](mailto:shareholderenquiries@imugene.com)

**Media Enquiries**  
Matt Wright  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Follow us on Twitter and Instagram @TeamImugene  
Like us on Facebook @Imugene  
Connect with us on LinkedIn @Imugene Limited  
Watch us on YouTube @ImugeneLimited

#### References

<sup>1</sup> Warner SG, Kim SI, Chaurasiya S, O’Leary MP, Lu J, Sivanandam V, Woo Y, Chen NG, Fong Y. A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression. *Mol Ther Oncolytics*. 2019 Apr 11;13:82–92. doi: 10.1016/j.omto.2019.04.001. PMID: 31061881; PMCID: PMC6495072.



## About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer Imugene Limited,*